melphalan (alkeran) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Melphalan, also known as L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent which produces a number of DNA adducts with the DNA interstrand crosslink (ICL) considered to be the critical cytotoxic lesion. Melphalan is used to treat different cancers including myeloma, melanoma and ovarian cancer.   NCATS

Chemistry

  • SMILES: N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(=O)O
  • InChIKey: SGDBTWWWUNNDEQ-LBPRGKRZSA-N
  • Mol. Mass: 305.21
  • ALogP: 1.93
  • ChEMBL Molecules:
    melphalan  
    melphalan hydrochloride  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$1.6111

United States

$7.3438 - $848.8900
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-(p-(bis(2-chloroethyl)amino)phenyl)-l-alanine | 3-p-(di(2-chloroethyl)amino)-phenyl-l-alanine | 4-(bis(2-chloroethyl)amino)-l-phenylalanine | aikeran | alanine nitrogen mustard | alkeran | cb-3025 | l-3-(p-(bis(2-chloroethyl)amino)phenyl)alanine | levofalan | levofolan | levopholan | l-pam | l-phenylalanine mustard | l-sarcolysin | l-sarcolysine | melfalan | melfalano | melflufen | melphalan | melphalan-flufenamide | melphalan hcl | melphalan hydrochloride | melphalanum | p-bis(beta-chloroethyl)aminophenylalanine | p-di-(2-chloroethyl)amino-l-phenylalanine | phenylalanine mustard | phenylalanine nitrogen mustard | p-l-sarcolysin | p-n-bis(2-chloroethyl)amino-l-phenylalanine | p-n,n-bis(2-chloroethyl)amino-l-phenylalanine | sarcoclorin

Organizations (402)

Research & Development (381)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (208)

Approved Indications (3)


 

Carcinoma

Multiple Myeloma

Ovarian Neoplasms (approved 1964)

Experimental Indications - Clinical Trial Phases 1-4 (207)


 

Adenocarcinoma, Clear Cell (Phase 1)

Adenoma, Islet Cell (Phase 2)

Adrenoleukodystrophy (Phase 2)

Agammaglobulinemia (Phase 2)

Allergy and Immunology (Phase 1/Phase 2)

Allogeneic Cells (Phase 2)

Amyloidosis (Phase 3)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Anemia, Diamond-Blackfan (Phase 2)

Anemia, Refractory (Phase 2)

Anemia, Sickle Cell (Phase 3)

Angiogenesis Modulating Agents (Phase 2)

Antigens, CD19 (Phase 1/Phase 2)

Antigens, CD20 (Phase 1)

Appendiceal Neoplasms (Phase 2)

Astrocytoma (Phase 1/Phase 2)

Autoimmune Diseases (Phase 2)

Autoimmune Diseases of the Nervous System (Phase 2)

Autoimmune Lymphoproliferative Syndrome (Phase 2)

beta-Thalassemia (Phase 2)

Bile Duct Neoplasms (Phase 2/Phase 3)

Bone Marrow Cells (Phase 2)

Bone Marrow Failure Disorders (Phase 2)

Bone Marrow Transplantation (Phase 2)

Brain Neoplasms (Phase 2)

BRCA1 Protein (Phase 2)

Breast Neoplasms (Phase 3)

Breast Neoplasms, Male (Phase 2)

Burkitt Lymphoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Cerebellar Diseases (Phase 2)

Chediak-Higashi Syndrome (Phase 2)

Child (Phase 2)

Cholangiocarcinoma (Phase 2/Phase 3)

Chordoma (Phase 1)

Choroid Plexus Neoplasms (Phase 1)

Chromosome Aberrations (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Common Variable Immunodeficiency (Phase 2)

Congenital Bone Marrow Failure Syndromes (Phase 2)

COVID-19 (Phase 2)

Cystic Fibrosis (Phase 2)

Desmoplastic Small Round Cell Tumor (Phase 2)

Diagnosis (Phase 3)

Diffuse Intrinsic Pontine Glioma (Phase 1)

DiGeorge Syndrome (Phase 2)

Diploidy (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Encephalitis (Phase 2)

Endoscopy (Phase 2)

Ependymoma (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Fanconi Anemia (Phase 2)

Fibrosarcoma (Phase 2)

Ganglioneuroblastoma (Phase 2)

Gangliosidosis, GM1 (Phase 2)

Geriatrics (Phase 2)

Glioma (Phase 1/Phase 2)

Graft vs Host Disease (Phase 2)

Granulomatous Disease, Chronic (Phase 2)

Hair (Phase 2)

Hamartoma (Phase 1)

Hematologic Diseases (Phase 2)

Hematologic Neoplasms (Phase 2)

Hematology (Phase 2)

Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)

Hemoglobinopathies (Phase 1/Phase 2)

Hemoglobinuria, Paroxysmal (Phase 3)

Histiocytosis (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

HIV (Phase 2)

HIV Infections (Phase 1/Phase 2)

Hodgkin Disease (Phase 3)

Immune System Diseases (Phase 2)

Immunoglobulin Light-chain Amyloidosis (Phase 3)

Immunoglobulin Light Chains (Phase 3)

Immunoglobulin M (Phase 2)

Immunologic Deficiency Syndromes (Phase 2)

Infections (Phase 2)

Inflammation (Phase 2)

Inflammatory Breast Neoplasms (Phase 2)

Intestinal Neoplasms (Phase 2)

Kidney Failure, Chronic (Phase 2)

Kidney Neoplasms (Phase 2)

Lambert-Eaton Myasthenic Syndrome (Phase 2)

Leukemia (Phase 3)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Erythroblastic, Acute (Phase 2)

Leukemia, Hairy Cell (Phase 2)

Leukemia, Large Granular Lymphocytic (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 3)

Leukemia, Plasma Cell (Phase 2)

Leukemia, Prolymphocytic (Phase 2)

Leukemia, Prolymphocytic, B-Cell (Phase 2)

Leukemia, Prolymphocytic, T-Cell (Phase 2)

Leukemia, T-Cell (Early Phase 1)

Leukodystrophy, Globoid Cell (Phase 2)

Leukodystrophy, Metachromatic (Phase 2)

Liver Neoplasms (Phase 2)

Lymphohistiocytosis, Hemophagocytic (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Lymphomatoid Granulomatosis (Phase 2)

Lymphoproliferative Disorders (Phase 2)

Medulloblastoma (Phase 2)

Melanoma (Phase 3)

Metabolic Diseases (Phase 2)

Metabolism (Phase 1)

Mucolipidoses (Phase 2)

Mucopolysaccharidosis III (Phase 2)

Mucositis (Phase 3)

Multiple Myeloma ()

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Mutation (Phase 2)

Myasthenia Gravis (Phase 2)

Myelodysplastic-Myeloproliferative Diseases (Phase 2/Phase 3)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasm, Residual (Phase 2)

Neoplasms (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Neoplasms, Neuroepithelial (Early Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Nerve Sheath Neoplasms (Phase 2)

Neuroblastoma (Phase 3)

Neuroectodermal Tumors (Phase 1/Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Neuromyelitis Optica (Phase 2)

Neutropenia (Phase 2)

Oligodendroglioma (Phase 1/Phase 2)

Opsoclonus-Myoclonus Syndrome (Phase 2)

Organ Transplantation (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Patient Participation (Phase 1/Phase 2)

Pediatrics (Phase 1)

Plasmablastic Lymphoma (Phase 1/Phase 2)

Plasmacytoma (Phase 2)

Pneumonia, Viral (Phase 2)

Polycythemia Vera (Phase 2)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 2)

Precancerous Conditions (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2/Phase 3)

Preleukemia (Phase 1/Phase 2)

Primary Immunodeficiency Diseases (Phase 2)

Primary Myelofibrosis (Phase 2)

Prognosis (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2/Phase 3)

Retinal Neoplasms (Phase 2)

Retinoblastoma (Phase 3)

Rhabdoid Tumor (Phase 1)

Rhabdomyosarcoma (Phase 2)

Sandhoff Disease (Phase 2)

Sarcoma (Phase 3)

Sarcoma, Alveolar Soft Part (Phase 2)

Sarcoma, Ewing (Phase 3)

Sarcoma, Myeloid (Phase 2)

Severe Combined Immunodeficiency (Phase 2)

Sezary Syndrome (Phase 2)

Shwachman-Diamond Syndrome (Phase 2)

Smoldering Multiple Myeloma (Phase 2)

Spinal Diseases (Phase 1)

Stem Cell Transplantation (Phase 1/Phase 2)

Stiff-Person Syndrome (Phase 2)

Tay-Sachs Disease (Phase 2)

Testicular Neoplasms (Phase 2)

Thrombocythemia, Essential (Phase 2)

Thymoma (Phase 2)

Translocation, Genetic (Phase 2)

Transplantation (Phase 2)

Transplantation, Autologous (Phase 2)

Transplantation, Homologous (Phase 2)

Vasculitis, Central Nervous System (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Wilms Tumor (Phase 1)

Wiskott-Aldrich Syndrome (Phase 2)

Wolman Disease (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 682
  • # of Trial Organizations: 381

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue